Literature DB >> 30826629

The effect of perampanel on aggression and depression in patients with epilepsy: A short-term prospective study.

Hiroko Goji1, Kousuke Kanemoto2.   

Abstract

PURPOSE: Using specialized tools, we assessed patients receiving perampanel (PER) to investigate its effects on aggression and depression, as well as the impact of other concomitant antiepileptic drugs (AEDs) on those conditions.
METHOD: Seventy-seven patients with epilepsy were initially enrolled, then examined at entry and 12 weeks later (endpoint). At both examinations, assessments were performed with the Buss Perry Aggression Questionnaire (BAQ) and Neurological Disorders Depression Inventory for Epilepsy (NDDI-E). Ultimately, 59 patients completed the study.
RESULTS: Total BAQ (p = 0.013) and NDDI-E (p = 0.000) scores at the endpoint were significantly increased in comparison with those at entry. Analysis with 4 subscales showed increases in both verbal and physical aggression, while multivariate analysis revealed that concomitant AED administration did not have a significant impact on the increase of BAQ or NDDI-E score. A dose-dependent effect of PER was confirmed in BAQ, but not NDDI-E results. PER was discontinued due to adverse psychiatric effects in 3.9% of the patients.
CONCLUSIONS: The present findings indicate that PER increases assessment scores indicative of aggression as well as depression. No additional aggression-augmenting effect was seen with concomitant AED administration.
Copyright © 2019 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aggression; BAQ; Depression; NDDI-E; Perampanel

Mesh:

Substances:

Year:  2019        PMID: 30826629     DOI: 10.1016/j.seizure.2019.02.009

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  4 in total

1.  Hippocampal Proteomic Analysis in Male Mice Following Aggressive Behavior Induced by Long-Term Administration of Perampanel.

Authors:  Wu Yang; Lin Ma; Dong-Mei Hai; Ning Liu; Jia-Mei Yang; Xiao-Bing Lan; Juan Du; Li-Shan Yang; Tao Sun; Jian Qiang Yu
Journal:  ACS Omega       Date:  2022-06-01

2.  Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis.

Authors:  Christos Andronis; João Pedro Silva; Eftychia Lekka; Vassilis Virvilis; Helena Carmo; Konstantina Bampali; Margot Ernst; Yang Hu; Irena Loryan; Jacques Richard; Félix Carvalho; Miroslav M Savić
Journal:  Arch Toxicol       Date:  2020-06-05       Impact factor: 5.153

Review 3.  Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.

Authors:  Adam Strzelczyk; Susanne Schubert-Bast
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

4.  PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice.

Authors:  Vicente Villanueva; Wendyl D'Souza; Hiroko Goji; Dong Wook Kim; Claudio Liguori; Rob McMurray; Imad Najm; Estevo Santamarina; Bernhard J Steinhoff; Pavel Vlasov; Tony Wu; Eugen Trinka
Journal:  J Neurol       Date:  2021-08-24       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.